Lactobacillus rhamnosus GG: clinical aspects of the use from the perspective of evidence-based medicine

Abstract

This review provides information on the composition and functions of the intestinal microbiota, its role in the immune development. At present, prophylactic and therapeutic uses of probiotics are widely common for a variety of pathological conditions, however they have proven efficacy only in certain diseases. This review provides information on the efficacy of the use of probiotic microorganism L. rhamnosus GG in the paediatric practice as one of the most studied and tested strains. It summarized the currently available evidence on the efficacy of its use for the treatment of acute diarrhea, the prevention of antibiotic-associated diarrhoea and nosocomial infections, defined the role of L. rhamnosus GG in the prevention of respiratory tract infections and gastrointestinal infections in children, considered its therapeutic and preventive use in allergic diseases and other nosological forms. Special attention was paid to the effect of L. rhamnosus GG on the immune system functioning. The results of this strain test as adjuvant vaccines are also encouraging. The review describes the molecular mechanisms of action of L. rhamnosus GG, which provide immunomodulating effect of this strain. In addition, it presents data on the clinical efficacy of Normobact L synbiotic comprising a combination of LGG (4 x 109) and fructooligosaccharides (800 mg), which is approved for use in children in Russia.

Keywords

• probiotics
• lactobacillus rhamnosus gg
• immune response
• immunomodulation
• diarrhea
• atopic dermatitis
• adjuvants
• respiratory infections
• normobact l